Abud MC

Language: Spanish
References: 21
Page: 7-12
PDF size: 74.17 Kb.

Text Extraction

No abstract

REFERENCES

1. Dunlop DD, Manheim LM, Song J, Chang RW. Arthritis prevalence and activity limitations in older adults. Arthritis Rheum 2001; 44: 212-21.

2. Doherty M. Osteoarthritis. Ann Rheum Dis 2001; 60 (Suppl 1): 2.

3. Altmann RD, Hochberg MD, Moskowitz RW, Schnitzer TJ. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000; 43: 1905-15.

4. Pelletier JP, Pelletier JM, Abramson SB. Osteoarthritis, an inflammatory disease. Potential implications for the selection of new therapeutic targets. Arthritis Rheum 2001; 44: 1237-47

5. Nevitt MC, Felson DT, Williams EN, Grady D. For the Heart and Estrogen/progestin Replacement Study Research Group. The effect of estrogen plus progestin on knee symptoms and related disability in postmenopausal women: The Heart and Estrogen/Progestin Replacement Study, a Randomized double-blind, placebo-controlled trial. Arthritis Rheum 2001; 44: 811-8.

6. Gabriel SE. Evaluation of the patient: Epidemiology of the Rheumatic Diseases, in Kelley’s: Textbook of Rheumatology, 6th edition, Ruddy, Harris, Sledge eds., 2001; ch23: 321-33.

7. 6a. Wigley RD (ed), The primary prevention of rheumatic diseases. Lancs UK: Parthenon Publishing Group 1994.

8. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarhritis with a view to presentation. Arthritis Rheum 1998; 41: 1343.

9. Young A, Dixey J, Cox N, Davies P, Devlin J, Emery P, Gallivan S et al. How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow up in 732 patients from the Early RA Study (ERAS). J Rheumatol 2000; 39: 603-11.

10. Flato A, Aasland A, Vinje O et al. Outcome and predictive factors in juvenile rheumatoid arthritis and juvenile spondyloarthropathy. J Rheumatol 1998; 25: 366.

11. Edworthy SM. Clinical manifestations of systemic lupus erythematosus, in Kelley’s: Textbook of Rheumatology, 6th edition, Ruddy, Harris, Sledge eds., 2001; ch74: 1105-23.

12. Uramoto KM, Michet CJJ, Thumbo I et al. Trends in the incidence and mortality of systemic lupus erythematosus (SLE) 1950-1992. Arthritis Rheum 1999; 42: 46.

13. Campion EW, Glynn RJ, de Labry LO. Asymptomatic hyperuricemia: The risks and consequences. Am J Med 1987; 82: 421.

14. 12 a. Emerson B, Wigley R. En: referencia 6a, Capítulo 23. Metabolic causes of arthritis, pp 261-8.

15. Wolfe F, Ross K, Anderson I et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995; 38: 19.

16. Yu D (ed). Spondyloarthropathies. Rheum Dis Clin North Am 1998; 24: 663.

17. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340: 1888-99.

18. Lanas A, Bajador E, Serrano P, Fuentes J, Carreño S, Guarda J, Sanz M et al. Nitrovasodilators, low dose-aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000; 343: 834-9.

19. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial. JAMA 2000; 284: 1247-55.

20. Dougados M, Béhier JM, Jolchine I, Calin A, van der Heijde D, Olivieri I, Zeidler H, Herman H. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosis spondylitis: A six week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001; 44: 180-5.

21. Gabriel SE, Crowson CS, O’Fallon WM. Comorbidity in arthritis. J Rheumatol 1999; 26: 2475.